|Bid||0.2411 x 900|
|Ask||0.2570 x 1400|
|Day's Range||0.2420 - 0.2648|
|52 Week Range||0.1000 - 1.5600|
|Beta (5Y Monthly)||1.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.30|
NEWTOWN, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15. Dr. Fruchtman and Avi Oler, Senior VP, Corporate Development, will be available for 1x1 meetings scheduled through the Bio Partnering system. The Presentation will be available On Demand for event participants October 13-15 and at https://investor.onconova.com/events-and-presentations as of October 15th. About Onconova Therapeutics, Inc. Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova is in preclinical development with its novel, proprietary, CDK4/6 + ARK5 inhibitor, ON 123300. Onconova’s RAS pathway inhibitor, oral rigosertib, is currently in a Phase 1/2 investigator-initiated study (IIS) targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. Preclinical work with rigosertib in COVID-19 is underway as well.For more information, please visit https://www.onconova.com.Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova expectations regarding its clinical development plans and patents. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials and regulatory approval of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, our collaborations, and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.Press release contact informationCompany Contact:Avi Oler Onconova Therapeutics, Inc. 267-759-3680 email@example.com https://www.onconova.com/contact/
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Onconova Therapeutics (NASDAQ: ONTX) - P/E: 0.85 2. Genesis Healthcare (NYSE: GEN) - P/E: 1.5 3. Coherus BioSciences (NASDAQ: CHRS) - P/E: 7.13 4. Seneca Biopharma (NASDAQ: SNCA) - P/E: 9.82 5. Five Star Senior Living (NASDAQ: FVE) - P/E: 3.65Onconova Therapeutics has reported Q2 earnings per share at -0.04, which has decreased by 33.33% compared to Q1, which was -0.03. Onconova Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Genesis Healthcare has reported Q2 earnings per share at -0.2, which has decreased by 171.43% compared to Q1, which was 0.28. Genesis Healthcare does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Coherus BioSciences has reported Q2 earnings per share at 0.81, which has increased by 68.75% compared to Q1, which was 0.48. Coherus BioSciences does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Seneca Biopharma has reported Q2 earnings per share at -0.15, which has increased by 37.5% compared to Q1, which was -0.24. Seneca Biopharma does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Five Star Senior Living reported earnings per share at 0.1, whereas in Q1 earnings per share sat at -0.55. Five Star Senior Living does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * 5 Value Stocks To Watch In The Real Estate Sector * 12 Energy Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
During Q2, Onconova Therapeutics's (NASDAQ: ONTX) reported sales totaled $56.00 thousand. Despite a 43.2% in earnings, the company posted a loss of $7.34 million. In Q1, Onconova Therapeutics brought in $52.00 thousand in sales but lost $5.12 million in earnings.What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Onconova Therapeutics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed in a business. Generally, a higher ROCE suggests successful growth in a company and is a sign of higher earnings per share for shareholders in the future. In Q2, Onconova Therapeutics posted an ROCE of -0.46%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on ONTXReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.For Onconova Therapeutics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q2 Earnings Insight Onconova Therapeutics reported Q2 earnings per share at $-0.04/share, which did not meet analyst predictions of $-0.03/share.See more from Benzinga * Overview Of Value Stocks In The Healthcare Sector * Return On Capital Employed Overview: Onconova Therapeutics * 5 Value Stocks To Watch In The Healthcare Sector(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.